573704-48-0

Basic information

• Product Name: N-(2-chloro-3,5-dimethoxyphenyl)acetamide
• Synonyms: N-(2-chloro-3,5-dimethoxyphenyl)acetamide;N-(2-Chloro-3,5-Dimethoxy-Phenyl)-Acetamide(WX632034)
• CAS NO: 573704-48-0
• Molecular Formula: C₁₀H₁₂ClNO₃
• Molecular Weight: 229.66018
• Mol File: 573704-48-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2-chloro-3,5-dimethoxyphenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-chloro-3,5-dimethoxyphenyl)acetamide(573704-48-0)
• EPA Substance Registry System: N-(2-chloro-3,5-dimethoxyphenyl)acetamide(573704-48-0)

Safety Data

• Hazardous Substances Data: 573704-48-0(Hazardous Substances Data)

Upstream product

• 79257-61-7 N-(3,5-dimethoxy-phenyl)-acetamide 
• 10272-07-8 3.5-dimethoxyaniline 

Downstream Products

• 120758-03-4 2-chloro-3,5-dimethoxy-phenylamine 
• 1067983-46-3 C₉H₈ClNO₃ 

Relevant articles and documents

PYRIMIDINE FGFR4 INHIBITORS

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the b

PYRAZOLYL QUINAZOLINE KINASE INHIBITORS

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6

In our efforts to minimize the side effects associated with low selectivity against the other PDE isozymes, a novel class of 2-phenylquinazolin-4(3H)-one derivatives were designed and prepared as potent PDE5 inhibitors with high selectivity against PDE6.